Skip to main content
 
Exosome Diagnostics is pleased to partner with Cal Ripken, Jr. Click here to learn more and follow Cal's journey with us. 

Top navigation

  • COVID-19
  • Cal Ripken, Jr.
  • GSA Award
  • Provider Resources
  • Contact Us
  • +1 844 396 7663
Bio-Techne Exosome logo

Main navigation

  • Physicians
    • ExoDx™ Prostate Test: At-Home Collection Kit
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
  • Patients
    • The ExoDx Prostate Test
    • Physician Locator
    • Understanding PSA Levels
    • About Prostate Cancer
    • ZERO - The End of Prostate Cancer
    • Patient FAQs
    • Patient Assistance Program
    • Billing Information
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Events
    • News
    • Press
    • Webinars
    • Events

Top navigation

  • COVID-19
  • Cal Ripken, Jr.
  • GSA Award
  • Provider Resources
  • Contact Us
  • +1 844 396 7663

Press

  • Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

    Press May 09, 2018

  • Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test

    Press May 08, 2018

  • Exosome Diagnostics Obviates Tissue Biopsies

    Press Apr 17, 2018

  • Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

    Press Mar 20, 2018

  • Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor

    Press Mar 14, 2018

  • Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States

    Press Feb 23, 2018

  • Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed

    Press Feb 01, 2018

  • Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US

    Press Jan 25, 2018

  • Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology

    Press Jan 09, 2018

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

(844) 396-7663
exosomedx.info@bio-techne.com
266 Second Ave, Suite 200
Waltham, MA 02451

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

Iso LogoThis test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470.  Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2021 ExoDx

Bottom footer navigation

  • Privacy Policy